Alignment Healthcare (ALHC) opened 2026 with Q1 results that put revenue at about US$1.2b and basic EPS at roughly US$0.06, while trailing twelve month figures show revenue at about US$4.3b and basic EPS of about US$0.10 as the business stays in positive territory. The company has seen quarterly revenue move from US$701.2m in Q4 2024 to US$926.9m in Q1 2025 and then to US$1.2b in Q1 2026, with basic EPS shifting from a loss of about US$0.16 in Q4 2024 to a loss of about US$0.05 in Q1 2025 and then to a profit of about US$0.06 in Q1 2026. This gives a clearer view of how margins have evolved across the last five quarters.

See our full analysis for Alignment Healthcare.

With the latest numbers on the table, the next step is to set these revenue and EPS trends against the prevailing narratives to see which stories around growth, profitability and risk still hold up and which start to look out of date.

TTM profit of US$19.8m after previous losses

• On a trailing twelve month basis, Alignment Healthcare moved from a loss of US$128.0m at Q4 2024 to a profit of US$19.8m by Q1 2026, with TTM basic EPS shifting from a loss of US$0.67 to a profit of US$0.10.
• What bullish investors highlight is that this move into profitability lines up with their view that earnings growth can build on itself over time, yet the recent quarterly net income figures, which ranged from a loss of US$31.1m in Q4 2024 to a profit of US$11.4m in Q1 2026, also show how sensitive results have been to small shifts in margins and costs.
  • Bulls point to the company having become profitable within the past five years and a reported 20.7% annual earnings growth rate over that period, and the TTM swing from a loss of US$0.72m at Q4 2025 to a profit of US$19.8m at Q1 2026 is consistent with that story of improving profitability.
  • At the same time, the quarterly pattern across 2025, with basic EPS moving between a loss of US$0.05 and a profit of US$0.08, underlines that the path has not been a straight line, which bullish forecasts of about 39.7% annual earnings growth will need to factor in.

Bulls argue that this move into the black is only the first chapter in a longer earnings story, while skeptics see it as a good moment to stress test the optimistic case before assuming it continues at the same pace. 🐂 Alignment Healthcare Bull Case

Revenue at US$4.3b TTM with membership-focused growth story

• Trailing twelve month revenue reached about US$4.3b by Q1 2026 compared with about US$2.7b at Q4 2024, and quarterly revenue in the last six reported periods ranged from US$701.2m in Q4 2024 to US$1.2b in Q1 2026.
• Bears argue that even with this revenue base and analysts pointing to about 21.4% annual revenue growth, the combination of high medical costs and expansion spending could keep margins thin, and the net income line over the last six quarters, which includes losses of US$31.1m and US$11.0m as well as profits of US$15.7m and US$11.4m, shows how quickly profitability can move when costs or reimbursement change.
  • The cautious narrative focuses on risks such as potential Medicare Advantage reimbursement cuts and tougher oversight, and the past swings from quarterly losses to profits in 2025 and into Q1 2026 give some numerical backing to the idea that earnings could come under pressure again if those headwinds show up in the income statement.
  • On the other hand, the fact that TTM revenue rose from about US$3.0b at Q1 2025 to US$4.3b at Q1 2026 gives bears a reason to separate revenue growth, which is visible in the data, from the more open question of whether that growth will consistently translate into stable net income.

For a cautious investor, the key question is less about whether Alignment can add revenue and more about how much of that US$4.3b TTM top line ultimately falls to the bottom line. 🐻 Alignment Healthcare Bear Case

P/S around 1x against DCF value and analyst targets

• With the current share price at US$20.26, the data describes the stock trading at about 1x P/S, compared with a peer average around 1.7x and a US healthcare average around 1.2x, and also sitting below a DCF fair value of about US$41.45 and an analyst price target of about US$25.54.
• Consensus narrative supporters argue that the combination of a 39.7% annualized earnings growth figure, revenue growth forecasts around 21.4% a year, and this P/S discount helps explain why analysts see room between the current US$20.26 price and their US$25.54 target, but the same numbers also mean investors need to judge whether current profitability of US$19.8m TTM is enough to support those expectations.
  • The roughly US$4.3b TTM revenue and US$19.8m TTM net income imply that margins are still relatively slim, which gives context for why some analysts in the bearish cohort use lower price targets even while assuming revenue in the billions over time.
  • At the same time, the modelled gap between the share price of US$20.26 and the DCF fair value of about US$41.45, along with the P/S discount to peers and the broader healthcare group, is a concrete expression of the reward side of the risk reward trade off that readers can weigh against the regulatory and cost risks flagged in the narratives.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Alignment Healthcare on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Sentiment around Alignment Healthcare appears mixed. Consider this a cue to review the numbers, weigh the risks against the potential rewards, and form your own view using the full picture in 5 key rewards and 1 important warning sign.

See What Else Is Out There

Alignment Healthcare is profitable but runs on slim margins, with earnings and net income moving between losses and modest profits as costs and reimbursement shift.

If you want more stability in your portfolio, now is a good time to compare these swings with companies in the 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.